The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus

Scientific paper - Original scientific paper

• Author: Dubravka Bobek
• Author: Danka Grčević
• Author: Nataša Kovačić
• Author: Ivan Krešimir Lukić
• Author: Marija Jelušić
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

BACKGROUND:

The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. ----- METHODS:

Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. ----- RESULTS:

The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. ----- CONCLUSION:

The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.

• Keywords (english): Adolescent; Arthritis, Juvenile/diagnosis; Arthritis, Juvenile/metabolism; Biological Markers/metabolism; Blood Sedimentation; C-Reactive Protein/metabolism; Case-Control Studies; Child; Child, Preschool; HMGB1 Protein/metabolism; Humans; Lupus Erythematosus, Systemic/diagnosis; Lupus Erythematosus, Systemic/metabolism; Prospective Studies; Receptors, Immunologic/metabolism; Sensitivity and Specificity; Severity of Illness Index; Synovial Fluid/metabolism; alpha-Macroglobulins/metabolism
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Pediatric Rheumatology
• Numbering: vol. 12, no. 1, p. 50
• p-ISSN: 1546-0096
• DOI: https://doi.org/10.1186/1546-0096-12-50
• URN:NBN: urn:nbn:hr:105:974842
• Publication: 2014-12-03
• Document URL: https://doi.org/10.1186/1546-0096-12-50
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-27 20:16:02